It’s not only getting harder for small biotechs to find funding; too many have scaled up operations by adding employees too quickly, forcing them to lay off people as the path to new drug approvals gets more complicated.
Biotech
KEY TAKEAWAY: Small biotech companies are working to develop new drugs, but the operating structures that give them an advantage are often the first to disappear when they are acquired by big pharma.
POST SUMMARY: Over the holiday week I had the chance to catch up with some business colleagues over a beer and great Boston seafood appetizers. If you want an example how big pharma mentality can kill innovative biotech companies, look no further than the examples of Biogen and Amgen.